- PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database
Xiayang Ren et al, 2024, Expert Opinion on Drug Safety CrossRef - Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
Shuanghe Li et al, 2022, Journal of Clinical Medicine CrossRef - Safety of PARP inhibitors as maintenance therapy in ovarian cancer
Sabrina Chiara Cecere et al, 2023, Expert Opinion on Drug Safety CrossRef - Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data
Michael Friedlander et al, 2023, American Society of Clinical Oncology Educational Book CrossRef - Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC)
Walaa Bayoumie El Gazzar et al, 2023, Journal of Oncology Pharmacy Practice CrossRef